Tag Archive for: artificial intelligence

By nearly unanimous consent artificial intelligence reached an inflection point for pharma marketers in 2023. The question of how best to take advantage of this new tool to support brands and help patients, though, remains to be seen.

In 2024, the industry must acknowledge the interconnected impact of the Inflation Reduction Act (IRA), growing AI and technology usage, and evolving smart data, as these factors create a ripple effect. How market access responds to these effects will impact sales and marketing. Effectively addressing these impacts lies at the heart of industry reform.

Pharma commercial leaders are understandably energized by the prospect of leveraging emerging technology (e.g., advanced AI tools) to amplify the velocity and impact of their promotional efforts. While this potential lies ahead, commercial leaders must first address the age-old organizational challenges that continue to stand in the way of a fully coordinated and customer-centric promotional infrastructure.

Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.

MedAdNews talked to Jane Reed, director of life sciences with Linguamatics, an IQVIA company, about how pharma companies are using new AI-based technologies to advance their safety processes and other topics.

2024 will be the year that AI integration will be pivotal to the continued success of those working throughout biotech and life sciences, especially for those involved in the drug discovery and regulation processes.

Short- and long-term use cases recommended by experts.

As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. There are the usual suspects like evolving provider models, the continued transition to value-based care, and pharma and biotech companies’ increased investment in “access,” but there are two trends that are at the top of the “what we’re watching” list for 2024.

Many telehealth policies expanded during the pandemic have been extended through December 31, 2024. Beyond that, policymakers will need to make hard decisions or continue with temporary extensions. Either way, a range of changes in telehealth are coming and will impact reimbursement policies, technology infrastructure, privacy, provider and patient/member adoption, and economic factors.

If you’re a student of history – or recently saw the popular movie “Oppenheimer”, you know just how pivotal of a figure J. Robert Oppenheimer is. He is forever linked to the development of one of the most powerful and dangerous creations in history – the atomic bomb. Drawing parallels to artificial intelligence, Faruk Capan of EVERSANA explains the ethical and societal impacts of the technology.